Novartis' lung cancer drug gets breakthrough designation

03/19/2013 | PharmaTimes (U.K.)

The FDA granted breakthrough therapy status to Novartis' LDK378 for treatment of patients with anaplastic lymphoma kinase positive metastatic nonsmall-cell lung cancer when crizotinib can't be used. The drug is being tested in two midstage trials, and Novartis plans to initiate several late-stage studies this year. An initial regulatory application is expected early next year.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA